Tours, France – 25 Fév 2021 – The European Patent Office (EPO) has granted the patent number EP3521314 on the McSAF Inside® technology to access DAR 4 antibody-drug conjugates, an emerging class of targeted medicines. This completes the portfolio of granted patents in France (FR3008408), Japan (JP6533222) and United States of America (US10307488). This is an essential asset for McSAF to become a key player in the bioconjugation field in the future. To know more
